08 August 2017
Visiongain has launched a new pharma report Rheumatoid Arthritis (RA) Drugs Market 2017-2027: Trends, Progress and Revenue Forecasting: Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs and Other Agents) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra and Biosimilars; Assessment of Leading Companies Including AbbVie, Roche, J&J, Amgen, Pfizer and Merck & Co.; Prediction of Leading National Markets (US, Japan the EU5 and BRIC); and Investigation of Late-Stage R&D Including IL-6, JAK, BTK and GM-CSF Inhibitors
Rheumatoid arthritis (RA) is an autoimmune disorder which primarily affects the synovial joints but also has systemic complications. It is a chronic progressive disease which increases the risk of cardiovascular morbidity and can shorten life expectancy. It affects between 0.5% and 1.0% of the population.
Demand for RA drugs is on the rise, particularly in developing countries. The TNF inhibitors, which have dominated the market so successfully, are now coming to the end of their patents, opening the way for new biologics and biosimilars to compete for their share of the market. Following the launch of Xeljanz there are other oral DMARDs in development which could potentially undermine the role of the biologics. Changes in the next few years will be critical in determining the future treatment for RA.
The lead Visiongain report analyst for this report commented; “The next ten years offers RA patients the possibility of having cheaper, more-targeted, and more-convenient drugs for their condition. The TNF inhibitors have been very lucrative drugs for manufacturers, but very expensive ones for patients. The rise to prominence of the biosimilars provides a way of reducing the cost of treatment but retaining the same level of efficacy. The introduction of new biologics, such as IL-6 inhibitors, could provide more-targeted drugs with greater levels of efficacy, while the arrival of new JAK inhibitors and BTK inhibitors could provide oral treatments which reduce the need for biologics. There are a lot of opportunities for new drugs in RA, and it is going to be interesting to see how the market develops.”
The Rheumatoid Arthritis (RA) Drugs market is highly competitive with many different players entering the market. The report discusses selected leading companies in the market. Notable companies in the RA Drugs market are Abbvie, Roche, Johnson & Johnson, Amgen, Pfizer, Merck & Co., Bristol-Myers Squibb and UCB.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.